IPCA Laboratories

IPCA Laboratories P/TBV

The Price to Tangible Book Value (P/TBV) of IPCA Laboratories (IPCALAB.NS) as of Nov 3, 2026 is 4.77. In the previous year, Price to Tangible Book Value (P/TBV) was 5.64 — a change of -15.48% (lower).

P/TBV

4.77

YoY

-15.48%

Last updated:

Price to Tangible Book Value (P/TBV) of IPCA Laboratories is 2026 4.77 . Price to Tangible Book Value (P/TBV) of IPCA Laboratories was 2025 5.64 . It decreases by -15.48% lower compared to the previous year.

The IPCA Laboratories P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2019
13.13 INR
Jan 1, 2020
11.10 INR
Jan 1, 2021
8.38 INR
Jan 1, 2022
7.24 INR
Jan 1, 2023
6.74 INR
Jan 1, 2024
6.24 INR
Jan 1, 2025
5.64 INR
Jan 1, 2026
4.77 INR
The IPCA Laboratories P/TBV history
YEARP/TBVYoY
4.77-15.48%
5.64-9.58%
6.24-7.45%
6.74-6.84%
7.24-13.65%
8.38-24.49%
11.10-15.47%
13.13-11.74%
14.87-8.02%
16.17-8.55%
17.68-2.56%
18.15-9.97%
20.16—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

Price to Tangible Book Value (P/TBV) of IPCA Laboratories is 4.77 in 2026.

Price to Tangible Book Value (P/TBV) of IPCA Laboratories changed from 5.64 to 4.77, representing a -15.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s IPCA Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — IPCA Laboratories

All Key Metrics — IPCA Laboratories